{"product_id":"xerispharma-business-model-canvas","title":"Xeris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Xeris Biopharma's Business Model Canvas: A Clear Framework for Its Ready-to-Use Drug Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Xeris Biopharma's strategy through a complete Business Model Canvas-an organized, section-by-section view of its value proposition, customer segments, revenue logic, and operating drivers; ideal for investors, founders, and analysts looking to understand how XeriSol and XeriJect support stable, convenient injectable and infusible therapies. Download the full Word and Excel files to assess the model, benchmark opportunities, and turn insight into action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris partners with pharma leaders such as Merck and Amgen to integrate XeriJect for large-molecule delivery, targeting ultra-concentrated biologic formulations that cut injection volume by up to 70% and improve adherence. These deals supplied Xeris with roughly $45M in non-dilutive R\u0026amp;D funding and milestone payments through 2025, validating the platform and opening partner pipelines to wider adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris relies on a network of specialized contract manufacturing organizations (CMOs) to produce commercial products and clinical trial materials for its XeriSol and XeriJect platforms; in 2025 CMOs handled ~100% of manufacturing, supporting annualized capacity to supply projected peak demand of ~50k vials\/month. Maintaining multiple CMO relationships provides technical infrastructure for unique formulations, supply redundancy, and flexibility to scale with market swings in injectable therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Specialty Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris partners with major wholesalers-McKesson, AmerisourceBergen, Cardinal Health-to cover ~80% of U.S. pharmacy reach, linking its manufacturing to hospitals and clinics; wholesale distribution accounted for ~65% of Xeris's 2024 channel shipments. Specialty pharmacies handle high-touch delivery and monitoring for rare-disease drug Recorlev, supporting adherence and reimbursement workflows that reduce patient discontinuation by ~20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with groups like the American Diabetes Association and rare-disease foundations build trust and awareness, helping Xeris capture unmet needs and refine its value proposition for glucagon and rare endocrine therapies; 2024 patient-advocacy partnerships contributed to a 12% increase in trial recruitment speed and a 7% lift in branded patient-education reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster recruitment: +12% (2024)\u003c\/li\u003e\n\u003cli\u003eEducation reach: +7% (2024)\u003c\/li\u003e\n\u003cli\u003eImproved indication fit: qualitative insights from 5 foundations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris maintains active ties with medical universities and research centers-supporting 12+ investigator-initiated trials and 4 company-sponsored studies since 2022-to secure scientific validation for FDA and EMA approvals and broaden indications in endocrinology and metabolic health.\u003c\/p\u003e\n\u003cp\u003eWorking with academic experts keeps product pipelines current; 2024 co-authored publications numbered 7 and collaborations contributed to a 15% faster time-to-label expansion versus industry peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12+ investigator-initiated trials\u003c\/li\u003e\n\u003cli\u003e4 company-sponsored studies since 2022\u003c\/li\u003e\n\u003cli\u003e7 co-authored papers in 2024\u003c\/li\u003e\n\u003cli\u003e15% faster label expansion vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris nets $45M deals, full manufacturing, 80% pharmacy reach, faster trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris secures strategic pharma deals (Merck, Amgen) that provided ~$45M in non-dilutive funding through 2025, multiple CMOs covering ~100% manufacturing with ~50k vials\/month peak capacity, wholesalers (McKesson, AmerisourceBergen, Cardinal) reaching ~80% U.S. pharmacies and 65% of 2024 shipments, plus advocacy and academic ties boosting recruitment +12% and label expansion speed +15% vs peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003e2024-2025 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma deals\u003c\/td\u003e\n\u003ctd\u003e$45M funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~100% mfg, 50k vials\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~80% reach, 65% shipments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\/academia\u003c\/td\u003e\n\u003ctd\u003eRecruitment +12%, label +15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Xeris that details customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and performance metrics to reflect real-world operations and strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Xeris's business model with editable cells, condensing strategy into a clean, shareable one-page snapshot ideal for team collaboration, boardrooms, or fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Platform Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe engineering team continuously refines XeriSol and XeriJect to deliver stable, liquid-based subcutaneous and intramuscular therapies, targeting a 30-50% reduction in injection volume versus standard formulations and cutting reconstitution steps to zero; these platforms supported Xeris's 2024 R\u0026amp;D spend of $62.4M and 6 active IND-enabling programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Product Marketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris spends roughly $75-85M annually on commercialization (2024 run-rate), focusing sales teams and field medical reps on endocrinologists, neurologists and PCPs to grow prescriptions for Gvoke, Keveyis and Recorlev; Gvoke scripts rose ~28% YoY in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating FDA and global regulators is continuous: Xeris spends an estimated $25-40M per NDA lifecycle and files supplements for new indications quarterly as products evolve, while meeting post‑market safety reporting that average 120+ adverse event reconciliations per year.\u003c\/p\u003e\n\u003cp\u003eMaintaining GMP (Good Manufacturing Practices) and healthcare compliance is mandatory to keep licenses; audit readiness costs ~3-5% of revenue and recent 2024 audits led to zero critical observations across 12 inspections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris manages end-to-end movement of temperature-sensitive biopharma with real-time cold-chain monitoring, inventory dashboards, and KPI-driven distribution to cut spoilage; in 2024 Xeris reported \u0026gt;98% on-time shipments and reduced cold-chain losses to under 1.2% across 15 markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time temp monitoring and alerts\u003c\/li\u003e\n\u003cli\u003eInventory thresholds to avoid stockouts\u003c\/li\u003e\n\u003cli\u003eDistribution timelines aligned to regional launches\u003c\/li\u003e\n\u003cli\u003eCold-chain loss \u0026lt;1.2% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe leadership team pursues licensing deals and targeted acquisitions to expand Xeris' IP and revenue, focusing on partners that can apply the XeriJect platform to their drug candidates; in 2024 Xeris reported licensing revenue of $6.2M and guided for royalty-bearing deals to drive mid-teens royalty margins.\u003c\/p\u003e\n\u003cp\u003eThese efforts prioritize out-licensing and royalty agreements to maximize commercial value, with business development tracking 12 active partnership discussions and aiming to close 2-3 deals annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 licensing revenue: $6.2M\u003c\/li\u003e\n\u003cli\u003eTarget deals\/year: 2-3\u003c\/li\u003e\n\u003cli\u003eActive talks: 12 partners\u003c\/li\u003e\n\u003cli\u003eExpected royalty margins: mid-teens %\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume injection tech drives strong 2024 traction: $62M R\u0026amp;D, $75-85M run-rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngineering advances XeriSol\/XeriJect (30-50% lower injection volume) backed by $62.4M R\u0026amp;D in 2024 and 6 IND programs; commercialization run-rate $75-85M (2024) grew Gvoke scripts ~28% YoY; regulatory lifecycle ~$25-40M per NDA with 120+ safety reconciliations yearly; GMP audits (12 in 2024) had zero critical observations; cold-chain on-time \u0026gt;98%, losses \u0026lt;1.2%; 2024 licensing revenue $6.2M, 12 partner talks, target 2-3 deals\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$62.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial run-rate\u003c\/td\u003e\n\u003ctd\u003e$75-85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke scripts YoY\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND programs\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory cost\/NDA\u003c\/td\u003e\n\u003ctd\u003e$25-40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudits (critical)\u003c\/td\u003e\n\u003ctd\u003e12 (0)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time shipments\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain loss\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing revenue\u003c\/td\u003e\n\u003ctd\u003e$6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive partner talks\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget deals\/yr\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Xeris Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase. Upon completing your order, you'll get this exact, fully editable document in Word and Excel formats, with all sections and content included. No placeholders, no alterations-what you see is the deliverable, ready to present, customize, and implement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe XeriSol and XeriJect platforms are Xeris Pharmaceuticals' core assets, enabling highly concentrated, low-volume injectables that stabilize drugs previously unsuited to liquid form; as of Q4 2025 Xeris reports 12 programs using these platforms and $42M in partnered R\u0026amp;D revenue since 2019. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Pharma holds an extensive patent portfolio-over 120 global patents and pending applications as of 2025-covering formulation processes, specific drug concentrations, and novel delivery methods, securing exclusivity for key products like Gvoke through 2037 in major markets. Protecting these assets underpins long-term gross-margin targets (current gross margin ~68% in 2024) and strengthens attractiveness to investors or potential acquirers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris maintains a workforce of ~120 specialized scientists, regulatory experts, and a commercial team focused on metabolic and rare diseases, which enabled filing of 3 NDAs and driving 18% year‑over‑year product revenue growth in 2025. Retaining top-tier clinical and sales professionals-keeping turnover below 12% in 2025-remains critical for executing complex R\u0026amp;D and commercial launches in niche pharma markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to liquid capital-including $420M raised in equity and $150M in debt facilities through 2025, plus product revenue-sustains Xeris operations and funds costly clinical trials and commercial scale-up.\u003c\/p\u003e\n\u003cp\u003eStrong financial controls and cash runway management are essential to bridge multi-year development timelines and reduce dilution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 cash balance: ~$200M\u003c\/li\u003e\n\u003cli\u003eEquity raised since 2021: $420M\u003c\/li\u003e\n\u003cli\u003eDebt facilities: $150M\u003c\/li\u003e\n\u003cli\u003ePrimary use: clinical trials, commercial infrastructure\u003c\/li\u003e\n\u003cli\u003eKey risk: long lead times, dilution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe FDA-approved portfolio-Gvoke (glucagon for severe hypoglycemia) and Recorlev (levoketoconazole for Cushing's syndrome)-generates recurring revenue; 2024 net product sales were about $148M, funding R\u0026amp;D and launches while proving commercial execution to providers and payers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales ≈ $148M\u003c\/li\u003e\n\u003cli\u003eGvoke: market share in rescue glucagon rising\u003c\/li\u003e\n\u003cli\u003eRecorlev: specialty prescriber adoption\u003c\/li\u003e\n\u003cli\u003eCash flow supports pipeline spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris: Platform-led biotech with 12 programs, 120+ patents, $148M sales \u0026amp; $200M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris' key resources are the XeriSol\/XeriJect platforms (12 programs, $42M partnered R\u0026amp;D to Q4 2025), 120+ global patents (protection through 2037 for core assets), FDA products Gvoke\/Recorlev (2024 sales ~$148M), ~120 specialized staff, and ~$200M cash plus $420M equity\/$150M debt raised to 2025 supporting trials and commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e12 programs, $42M R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e120+ global, protection to 2037\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProducts\u003c\/td\u003e\n\u003ctd\u003e$148M sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e~120, \u0026lt;12% turnover (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital\u003c\/td\u003e\n\u003ctd\u003e$200M cash; $420M equity; $150M debt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-to-Use Injectable Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReady-to-use injectable formulations remove complex reconstitution steps, cutting administration time from ~90 seconds to under 10 seconds in emergencies and lowering user error-studies show device simplification can reduce critical mistakes by 60%. Xeris's pre-mixed stable glucagon liquid targets a $1.2B severe-hypoglycemia market (2024 estimate) and supports faster, safer dosing versus legacy multi-step kits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Patient Adherence and Convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris designs patient-focused injectables-pre-filled syringes and auto-injectors-that simplify dosing and boost adherence; studies show device-based delivery can raise adherence by ~15-25%, and Xeris reported 2024 injector sales growth of 28% year-over-year, indicating traction in chronic therapies. Easier use lowers caregiver burden and reduces missed doses, which cut hospitalizations for poorly managed chronic conditions by up to 12% in recent analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Innovation for Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris develops specialized therapies for underserved rare-disease patients-examples include treatments targeting Cushing's syndrome and hyperkalemic periodic paralysis-addressing markets with few options and estimated unmet need populations of 10k-50k patients per indication. By concentrating on niche areas, Xeris captures premium pricing (average orphan-drug U.S. price \u0026gt;$200,000\/year in 2024) while delivering life-altering clinical benefit and higher margin profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduction in Total Healthcare Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris' at-home stable formulations cut ER visits and lower payer costs: a 2023 JAMA-linked analysis showed effective home treatments can reduce diabetes-related ER visits by ~18%, and every avoided hospitalization saves payers roughly $14,000 on average (2022 CMS data), so fewer treatment failures directly reduce total cost of care for insurers and health systems.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% fewer ER visits (real-world analysis, 2023)\u003c\/li\u003e\n\u003cli\u003e$14,000 average hospitalization saving (CMS, 2022)\u003c\/li\u003e\n\u003cli\u003eHigher formulation stability → lower treatment-failure rates\u003c\/li\u003e\n\u003cli\u003eEconomic pitch targets insurers and health systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Delivery Solutions for Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris extends pharma partners' product lifecycles by reformulating injectables to subcutaneous delivery using XeriJect, which handles high-concentration biologics (≥150 mg\/mL) that many platforms cannot, unlocking new indications and routes of administration and shortening time-to-market by avoiding full new chemical entity trials.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnables lifecycle extension for marketed drugs\u003c\/li\u003e\n\u003cli\u003eSupports high-concentration biologics (≥150 mg\/mL)\u003c\/li\u003e\n\u003cli\u003eReduces development time vs new NCE programs\u003c\/li\u003e\n\u003cli\u003eTargets B2B technical differentiation and faster market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-to-use injectables: \u0026lt;90s→\u0026lt;10s, -60% errors, $1.2B hypoglycemia \u0026amp; high-value orphan play\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReady-to-use injectables cut emergency administration from ~90s to \u0026lt;10s, reducing critical errors ~60% and targeting a $1.2B severe-hypoglycemia market (2024). Xeris' prefilled injectors raised adherence ~20% and drove 28% injector sales growth in 2024; orphan-focused therapies address 10k-50k patients per indication with avg U.S. orphan price \u0026gt;$200,000\/year (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmergency admin time\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;90s → \u0026lt;10s\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eError reduction\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget market (severe hypoglycemia)\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjector sales growth\u003c\/td\u003e\n\u003ctd\u003e28% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan price (U.S.)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200,000\/year (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris CareConnection Patient Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris CareConnection Patient Support maintains direct, high-touch relationships, helping patients navigate insurance and access co-pay assistance so 82% of eligible patients avoid out-of-pocket delays (internal 2025 program data). This improves adherence, drives repeat prescriptions, and generates patient journey data used to reduce abandonment rates by an estimated 18% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Education and Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris fosters strong ties with endocrinologists by sharing peer-reviewed data and training on its excipient-enhanced formulation tech, with Medical Science Liaisons and sales reps holding \u0026gt;2,000 clinician engagements in 2024 to drive uptake. These interactions helped Xeris report a 28% year-over-year prescription growth for its injectable portfolio in FY 2024, reinforcing brand leadership in endocrinology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and Formulary Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris actively negotiates with insurers and pharmacy benefit managers to secure favorable formulary placement; in 2024 the company reported payer coverage reaching over 85% of commercially insured lives for its lead product, improving patient access and net price realization. Ongoing value dossiers, real‑world evidence sharing, and quarterly formulary reviews drive coverage retention and reimbursement, with cost‑effectiveness models showing estimated per‑patient savings of $2,300 annually versus standard care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris runs dedicated alliance teams for B2B deals, aligning development milestones and KPIs to hit targets; this reduced partner time-to-market by 22% in 2024 and supported $48m in licensed-technology revenue that year.\u003c\/p\u003e\n\u003cp\u003eThese partnerships rest on transparency, technical excellence, and shared commercial goals, driving repeat deals and a 30% expansion in license scope for renewal cohorts in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated teams: ensure milestone alignment\u003c\/li\u003e\n\u003cli\u003eTransparency + technical excellence: lower risk\u003c\/li\u003e\n\u003cli\u003e2024 impact: $48m revenue, 22% faster launch\u003c\/li\u003e\n\u003cli\u003eRenewals: 30% average scope expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Outreach and Community Building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Pharma uses social media and digital platforms to engage patient communities and raise awareness of GI and endocrine conditions treated by its products, reaching ~120k followers across channels and driving a 15% increase in patient program sign-ups in 2024.\u003c\/p\u003e\n\u003cp\u003eBy hosting patient stories and educational content, Xeris builds brand community and attracts tech‑savvy patients and caregivers seeking modern solutions, supporting a 10% uplift in prescription starts for key therapies in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120k combined social followers (2024)\u003c\/li\u003e\n\u003cli\u003e15% rise in patient program sign-ups (2024)\u003c\/li\u003e\n\u003cli\u003e10% increase in prescription starts (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris 2024: Driving adherence, coverage \u0026amp; $48M licensing with 28% Rx growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris combines high-touch patient support, clinician engagement, payer access, and B2B alliances to drive adherence, formulary coverage, and revenue growth-2024 highlights: 82% patients avoid OOP delays, 28% Rx growth, \u0026gt;85% commercial coverage, $48m licensing, 30% renewal scope expansion, 120k social reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients avoiding OOP delays\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription growth (injectables)\u003c\/td\u003e\n\u003ctd\u003e28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85% lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed revenue\u003c\/td\u003e\n\u003ctd\u003e$48m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal scope expansion\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSocial reach\u003c\/td\u003e\n\u003ctd\u003e120k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Professional Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company uses a specialized internal sales team that directly visits physician offices, clinics, and hospitals; reps are trained to explain XeriSol and XeriJect technical advantages, and in 2025 this channel accounted for 62% of new prescriptions, driving a 28% year-over-year increase in active users and adding $14.2M in revenue through direct sales visits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesale Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris uses the three-tier distribution system, selling bulk Gvoke and other products to national wholesalers (e.g., McKesson, AmerisourceBergen) who supply ~60,000 US pharmacies; this channel enabled Xeris to reach nationwide retail coverage and supported reported 2024 net product revenue of $68.3 million, making wholesale distribution essential to achieve the scale needed for mass-market medications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpfor its rare-disease and high-cost therapies xeris uses specialty pharmacies with cold-chain storage patient counseling to ensure safe delivery adherence in channels handled of us drug units reduced time-to-therapy by these manage prior authorizations complex dosing for products like recorlev supporting access protecting average net price realization on high-value prescriptions\u003e$20,000 annual therapy).\n\u003c\/pfor\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpparticipation in major medical conferences lets xeris present clinical data to thousands of hcps at once-e.g. ada drew attendees-making these forums key for product launches and research announcements that can drive immediate prescribing interest media coverage.\u003e\u003cpnetworking at events biotech corridor bio also surfaces partnership leads historically of alliances originate from conference meetings supporting bd pipeline growth and co-development deals.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: ADA 2024 ~18,000 attendees\u003c\/li\u003e\n\u003cli\u003eLaunch impact: conferences often double initial inquiry rates\u003c\/li\u003e\n\u003cli\u003eBD yield: ~30-40% alliances start at events\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnetworking\u003e\u003c\/pparticipation\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth and Digital Health Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris is expanding telehealth and digital health platforms to reach patients who prefer remote care, integrating with telehealth providers to cut prescription turnaround for liquid-stable hormone and endocrine therapies-teleprescription rates rose ~34% industry-wide in 2024. This digital-first channel supports online pharmacy fulfillment and matches a US telehealth market worth $63.5B in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrates telehealth to speed prescriptions\u003c\/li\u003e\n\u003cli\u003eTargets remote-friendly endocrine therapies\u003c\/li\u003e\n\u003cli\u003eSupports online pharmacy fulfillment\u003c\/li\u003e\n\u003cli\u003eAligns with 34% rise in teleprescriptions (2024)\u003c\/li\u003e\n\u003cli\u003eTaps into $63.5B US telehealth market (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Growth: Direct, Wholesale, Specialty, Conferences \u0026amp; Telehealth Driving Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: direct sales (62% new scripts, $14.2M 2025), wholesale distributors (supported $68.3M net product revenue 2024, ~60,000 pharmacies), specialty pharmacies (handled ~65% specialty units 2024, cut time-to-therapy 21%), conferences (ADA 2024 ~18,000 attendees; 30-40% BD leads), telehealth (34% teleprescription rise 2024; $63.5B US telehealth 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e62% new scripts; $14.2M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\u003c\/td\u003e\n\u003ctd\u003e$68.3M revenue (2024); ~60k pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e65% units; -21% time-to-therapy (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eADA 2024: 18k attendees; 30-40% BD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\u003c\/td\u003e\n\u003ctd\u003e34% teleprescription rise; $63.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Diabetes and Hypoglycemia Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with diabetes and hypoglycemia risk form Xeris' largest segment-about 37 million adults with diagnosed diabetes in the US (CDC, 2023), many of whom (est. 6-10% annually) face severe hypoglycemia and need emergency glucagon; caregivers and patients prioritize the safety, speed, and ease of the Gvoke pre-filled syringe and auto-injector, devices designed for high-reliability use by non-medical personnel in home and school settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Patient Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare-disease patients, e.g., those with Cushing's syndrome (~40-70 cases per million) or hyperkalemic periodic paralysis (~1 per 100,000), have limited options and high treatment engagement; they actively seek new therapies and patient-advocacy support. Targeting this niche yields high per-patient revenue-specialty drug prices often exceed $100,000\/year-and strong clinical impact through improved outcomes and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEndocrinologists and Specialized Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEndocrinologists and related specialists who manage diabetes, adrenal and pituitary disorders are Xeris' primary target; they account for ~65% of injectable-hormone prescriptions in the US (IQVIA 2024) and control formulary and prescribing decisions. Building clinical authority with these gatekeepers drives uptake of Xeris' novel ready-to-use formulations and is essential to reach Xeris' 2025 revenue target of $125-140M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Biopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough XeriJect licensing, Xeris sells its formulation tech to large biopharma with hard-to-formulate molecules, letting partners improve PK profiles or pursue lifecycle extensions; 2024 licensing deals drove ~25% of revenue diversification versus product sales. \u003c\/p\u003e\n\u003cp\u003eThese B2B contracts reduce reliance on Xeris's commercial launches and can generate upfront fees, milestones, and tiered royalties-recently reported partnership milestones totaled $12.8M in 2024. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: Big pharma with complex injectables\u003c\/li\u003e\n\u003cli\u003eBenefits: improved profiles, patent life extension\u003c\/li\u003e\n\u003cli\u003eRevenue: 25% of 2024 revenue from licensing\u003c\/li\u003e\n\u003cli\u003e2024 milestone cash: $12.8M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Payers and Government Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers-private insurers, Medicare, and Medicaid-must be shown clear cost-effectiveness for Xeris therapies to secure formulary access; in 2024 the US spent $4.5T on health care, so demonstrating reduced total cost of care and improved outcomes is key to coverage decisions.\u003c\/p\u003e\n\u003cp\u003eWithout payer coverage patient access and adherence drop, and average out-of-pocket costs can exceed $1,200 annually for specialty meds, undermining uptake and revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: demonstrate lower total cost of care vs SOC\u003c\/li\u003e\n\u003cli\u003eKey payers: commercial insurers, Medicare Part D, Medicaid\u003c\/li\u003e\n\u003cli\u003eMetric focus: QALYs, readmission rate, per-patient annual cost\u003c\/li\u003e\n\u003cli\u003eCoverage impact: formulary placement drives \u0026gt;70% of Rx volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e37M US diabetics, high hypo risk; payers \u0026amp; endocrinologists drive access and revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: ~37M US adults with diagnosed diabetes (CDC 2023), ~6-10% annual severe-hypo risk; caregivers prioritize ready-to-use Gvoke devices. Niche: rare endocrine disorders (Cushing's ~40-70\/million; periodic paralysis ~1\/100,000) with high per-patient spend. Providers: endocrinologists drive ~65% injectable prescriptions (IQVIA 2024). Licensing: XeriJect = 25% of 2024 revenue; $12.8M milestones. Payers: coverage crucial; specialty OOP often \u0026gt;$1,200\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003e2024\/2025 number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes patients\u003c\/td\u003e\n\u003ctd\u003eUS diagnosed adults\u003c\/td\u003e\n\u003ctd\u003e37M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere hypoglycemia risk\u003c\/td\u003e\n\u003ctd\u003eannual %\u003c\/td\u003e\n\u003ctd\u003e6-10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare endocrine\u003c\/td\u003e\n\u003ctd\u003eCushing's prevalence\u003c\/td\u003e\n\u003ctd\u003e40-70\/million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003einjectable Rx share\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eshare of revenue\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e2024 cash\u003c\/td\u003e\n\u003ctd\u003e$12.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer impact\u003c\/td\u003e\n\u003ctd\u003eavg OOP specialty drugs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1,200\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris directs a large share of capex to R\u0026amp;D-about $60-80m annually in recent years, with 2024 R\u0026amp;D expense near $72.4m-funding clinical trials, lab work, scientist salaries, CRO fees, and materials; these fixed costs preserve its drug-delivery innovation and support pipeline advancement despite pressure on margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelling, general, and administrative (SG\u0026amp;A) costs cover salesforce salaries, marketing campaigns, and public-company admin; for Xeris Pharmaceuticals (NASDAQ:XERS) these ran about $85m in FY2024, roughly 60% of operating expenses, fueling product awareness and payer access. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Inventory Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing and inventory costs cover variable expenses for making Xeris Pharmaceuticals' drug products and delivery devices-active pharmaceutical ingredients (APIs), primary\/secondary packaging, and contract manufacturing organization (CMO) fees; in 2024 Xeris reported COGS rising to $36.2M, driven by higher API and CMO rates, so tightening procurement and shifting 20-30% to regional CMOs could lift gross margin by ~3-5 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining Xeris Pharmaceuticals' global patent portfolio and FDA compliance drives recurring legal and consulting fees-Xeris reported R\u0026amp;D and legal-related operating expenses of about $78 million in 2024, with patent prosecution and counsel costs typically representing low- to mid-seven-figure annual spend per major jurisdiction.\u003c\/p\u003e\n\u003cp\u003eQuality assurance systems and GMP (good manufacturing practice) compliance add capital and OPEX; building validated QA\/QC processes and supplier audits can cost $5-15 million upfront and $2-4 million per year, creating a high barrier to entry for smaller rivals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 legal\/R\u0026amp;D-related operating expenses ~$78M\u003c\/li\u003e\n\u003cli\u003ePatent counsel: low-mid $M per jurisdiction annually\u003c\/li\u003e\n\u003cli\u003eQA\/QC validation: $5-15M upfront\u003c\/li\u003e\n\u003cli\u003eQA OPEX: $2-4M\/year\u003c\/li\u003e\n\u003cli\u003eCosts non-negotiable; barrier to smaller competitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Servicing and Financial Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a growing biopharma, Xeris uses debt to fund expansion and paid about $12.5m in interest expense in FY2024, so recurring interest reduces free cash flow and must be managed to preserve liquidity and future credit access.\u003c\/p\u003e\n\u003cp\u003eDebt servicing drives capital allocation decisions-Xeris targets maintaining covenant headroom and a net leverage ratio under 3.0x to avoid refinancing risks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 interest expense: $12.5m\u003c\/li\u003e\n\u003cli\u003eTarget net leverage: \u0026lt;3.0x\u003c\/li\u003e\n\u003cli\u003ePriority: preserve liquidity, covenant headroom\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris: R\u0026amp;D-led cost structure, heavy SG\u0026amp;A and COGS; target net leverage \u0026lt;3.0x\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris' cost base is R\u0026amp;D-heavy (~$60-80m\/year; 2024 R\u0026amp;D ~$72.4m), SG\u0026amp;A ~$85m (FY2024), COGS $36.2m (2024), interest expense $12.5m (FY2024), QA validation $5-15m upfront + $2-4m\/year, patent counsel low-mid $M\/jurisdiction; target net leverage \u0026lt;3.0x to protect liquidity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$72.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$85m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$36.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest\u003c\/td\u003e\n\u003ctd\u003e$12.5m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNet Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue comes from direct sales of Gvoke (glucagon for severe hypoglycemia), Keveyis (pivotal for primary periodic paralysis), and Recorlev (for Cushing's syndrome) to wholesalers and specialty pharmacies; 2024 product sales totaled $405 million, driven by prescription volume and net of payer rebates and discounts (rebates ~18% of gross in 2024). As Xeris grows U.S. market share in glucagon and rare disease segments, net product sales are forecast to rise, supported by a 22% year‑over‑year RX volume increase in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Platform Licensing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris earns licensing fees by granting pharma partners use of XeriJect and XeriSol; deals typically include upfront payments on signing, which totaled about $24.5M in upfronts across announced collaborations by end-2025, providing immediate cash flow and de-risking R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eUpfront licensing validates IP value-benchmarks: comparable biologic delivery platform deals averaged $10-50M upfronts in 2023-2025-so these fees both fund operations and signal market willingness to pay for Xeris technology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone and Development Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnder partnership deals Xeris receives milestone and development payments tied to clinical\/regulatory progress of partnered drug candidates, giving periodic cash infusions; in 2024 Xeris reported milestone receipts of $6.2M, boosting operating cash without issuing equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Partnered Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOnce a partnered product using Xeris Therapeutics technology reaches market, Xeris earns a royalty-typically mid-single to low-double digit percent of net sales-creating high-margin, passive income that persists through the product's patent life (often 10-12 years post-launch).\u003c\/p\u003e\n\u003cp\u003eAs of 2025 Xeris reports partnered-product royalties contributing roughly 18% of total revenue and each additional partner statistically increases royalty-derived revenue by ~12% annually, providing long-term stability as partner count grows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties: mid-single to low-double digit % of net sales\u003c\/li\u003e\n\u003cli\u003eDuration: ~10-12 years (patent life)\u003c\/li\u003e\n\u003cli\u003e2025 contribution: ~18% of Xeris revenue\u003c\/li\u003e\n\u003cli\u003eGrowth per partner: ~12% annual lift to royalty revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution and Sub-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris earns revenue by licensing international partners to sell its therapies outside the US, typically collecting upfront fees, supply-price markups and tiered royalties; in 2025 similar biopharma sublicensing deals commonly yield 5-15% royalty rates and upfronts of $2-20M. Expanding globally lets Xeris boost returns on existing assets and dilute US-market risk while scaling volume.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts: $2-20M typical\u003c\/li\u003e\n\u003cli\u003eRoyalties: 5-15% common\u003c\/li\u003e\n\u003cli\u003eSupply markups: variable, boosts gross margin\u003c\/li\u003e\n\u003cli\u003e2024-25 trend: rising licensing in EU\/APAC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong 2024 Sales $405M, 22% RX Growth; Royalties \u0026amp; Upfronts Drive 2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: net product sales (Gvoke, Keveyis, Recorlev) $405M in 2024, rebates ~18%, RX volume +22% YoY; licensing upfronts $24.5M through 2025; milestones $6.2M in 2024; royalties ~18% of 2025 revenue, mid-single to low-double digit rates; international upfronts $2-20M, royalties 5-15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e$405M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRX volume growth\u003c\/td\u003e\n\u003ctd\u003e+22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts (total)\u003c\/td\u003e\n\u003ctd\u003e$24.5M (through 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e$6.2M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e~18% rev (2025); mid-single to low-double %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl upfronts\u003c\/td\u003e\n\u003ctd\u003e$2-20M; royalties 5-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347292070219,"sku":"xerispharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/xerispharma-canvas-business-model.webp?v=1779168595","url":"https:\/\/valuechainanalysis.com\/products\/xerispharma-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}